The Ohio State University Corporate Engagement Office

Back to All Technologies

GLCNAC and GALNAC drug conjugates to treat liver diseases

College
College of Pharmacy
Researchers
Dong, Yizhou
Chen, Xiaofang "xiaofang"
Zhang, Xinfu
Licensing Manager
Dahlman, Jason "Jay"
(614)292-7945
dahlman.3@osu.edu

TS-037289 — Liver specific drug delivery

Liver diseases are a major cause of morbidity and mortality in the United States and frequently affect people between 40 and 60 years of age. Some current drugs to fight liver diseases do not accumulate efficiently in the liver and can cause harmful side effects. New methods to deliver drugs to th…

The Need

Liver diseases are a major cause of morbidity and mortality in the United States and frequently affect people between 40 and 60 years of age. Some current drugs to fight liver diseases do not accumulate efficiently in the liver and can cause harmful side effects. New methods to deliver drugs to the liver are critical to maximize the utilization of drugs for liver diseases and to minimize their side effects.

The Technology

Researchers at The Ohio State University led by Dr. Yizhou Dong have developed Glcnac and Galnac drug conjugates for liver-targeted therapies. They have designed and synthesized these conjugates by linking Galnac or Glcnac to different drugs (statins, sofosbuvir and etc.) through diverse linkers. These conjugates showed enhanced liver accumulation compared with original drugs. Further on, upon the interaction with enzymes in the liver, active drugs could be released efficiently and restored their efficacy. Consequently, these conjugates are expected to maximize the utilization of drugs for liver diseases and minimized their side effects.

Commercial Applications

  • Drug Delivery
  • Liver Disease

Benefits/Advantages

  • Enchanced drug delivery to liver